Description
According to many studies on glucagon immunoassay, it has been established that the antibody against the C - terminal fragment ( 19 – 29 ) of glucagon has specific binding with pancreatic glucagon, whereas the antibody against the N – terminal fragment ( 9 – 19 ) of glucagon has specific binding with both of pancreatic and intestinal glucagon ( total glucagon ). Once, 30K by Unger et. al had been widely used as an antibody specific for the C - terminal fragment of glucagon, but Nishino, Shima and Yanaihara et. al succeeded in producing pancreatic glucagon specific antibody using synthetic peptide with the C – terminal fragment ( 19 – 29 ) of glucagon as immunogen in 1981. This EIA kit has been developed by using polyclonal antibody against glucagon ( 19 – 29 ), synthetic glucagon as standard antigen and biotinylated glucagon as labeled antigen for the measurment of rat, mouse or human glucagon in plasma